Lanoteplase

BioDrugs

Volumn 13, Issue 3, 2000, Pages 217-224

  Bhana, Nila ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; LANOTEPLASE; RECOMBINANT PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOSIS;

EID: 0034036434     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013030-00006     Document Type: Review

References (27)

1. Machecourt J, Dumoulin J, Calop J, et al. Cost effectiveness ofthrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patient streated within 4 hours. Eur Heart J 1993 Jan; 14: 75-83
2. Hayes OW. Emergency management of acute myocardial infarction: Focus on pharmacologic therapy. Emerg Med Clin North Am 1998; 16 (3): 541-63
3. Van de Werf F. What do new lytics add to t-PA? Am Heart J1999 Aug; 138 (2 Pt 2): 115-20
4. Larsen GR, Metzger M, Henson K, et al. Pharmacokinetic anddistribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989 May 15; 73: 1842-50
5. Larsen GR, Timony GA, Horgan PG, et al. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem 1991 May 5; 266: 8156-61
6. Hansen L, Blue Y, Barone K, et al. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator. J Biol Chem 1988 Oct 25; 263: 15713-9
7. Matsuno H, Uematsu T, Nakashima M. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model. Br J Pharmacol 1993 Dec; 110: 1278-9
8. Lerakis S, Stouffer GA, Runge MS. New thrombolytics: what is under development? Biodrugs 1997 Jul; 8: 24-32
9. Becker RC. New thrombolytic, anticoagulants, and platelet antagonists: the future of clinical practice. J Thromb Thrombolysis 1999; 7 (2): 195-220
10. Kostis JB, Liao W-c, Beierle FA, et al. Single bolus regimen oflanoteplase in acute myocardial infarction: hemostatic evaluation vs. tPA in the In Time Study [abstract]. J Am Coll Cardiol 1999 Feb; 33 Suppl. A: 325
11. Ogata N, Ogawa H, Ogata Y, et al. Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction. Jpn Circ J 1998 Nov; 62: 801-6
12. Oka N, Furuya M, Hata K, et al. Fibrin-dependent plasminogenactivation, binding affinity to fibrin and fibrinolytic activity of lanoteplase (SUN 9216) [in Japanese]. Japanese Pharmacology and Therapeutics 1999; 27 (2): 19-25
13. Umemura K, Toshima Y, Nakashima M. Thrombolytic efficacyof a modified tissue-type plasminogen activator, SUN9216,in the rat middle cerebral artery thrombosis model. Eur J Pharmacol 1994 Sep 1; 262: 27-31
14. Umemura K, Wada K, Uematsu T. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and athromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 1993 Jul; 24:1077-81
15. Umemura K, Ishiye M, Kosuge K, et al. Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR 139317, in the rat cerebral infarction model. Eur J Pharmacol 1995 Feb 24; 275: 17-21
16. Furuya M, Oka N, Horikawa Y, et al. Thrombolytic activity in jugular vein thrombosis and bleeding potential of lanoteplase (SUN 9216) in rabbits [in Japanese]. Yakuri to Chiryo 1999 Feb; 27: 141-50
17. Liao W-C, Beierle FA, Stouffer BC, et al. Single bolus regimen of lanoteplase in acute myocardial infarction: pharmacokinetic evaluation from In Time-I Study [abstract]. Circulation 1997 Oct 21; 96 Suppl.: 260-1
18. Vachharajani N, Shyu W, Stouffer B, et al. Pharmacokinetics and pharmacodynamics of lanoteplase in healthy subjects[abstract]. Clin Pharmacol Ther 1999 Feb; 65: 180
19. Hata K, Komoriya K, Takada N, et al. Pharmacokinetic studies of lanoteplase, a novel tissue plasminogen activator (1): Plasma levels after a single bolus intravenous administrationin rats, rabbits and dogs [in Japanese]. Pharmacometrics 1997Jan; 53: 1-10
20. Hata K, Komoriya K, Takada N, et al. Pharmacokinetic studiesof lanoteplase, a novel tissue plasminogen activator (2): tissue distribution after a single bolus intravenous administration in rats [in Japanese]. Pharmacometrics 1997 Jan; 53: 11-21
21. Hata K, Komoriya K, Takada N, et al. Pharmacokinetic studies of lanoteplase, a novel tissue plasminogen activator (3): metabolism and excretion after a single bolus intravenous administration in rats [in Japanese]. Pharmacometrics 1997 Jan; 53: 23-8
22. den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of aweight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. Adouble-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998 Nov 17; 98: 2117-25
23. Yui Y, Kawai C, Hosoda S, et al. Safely and efficacy of i.v. bolusinjection of SUN9216 (modified tissue plasminogen activator) in acute myocardial infarction: clinical early phase II study [in Japanese]. Yakuri to Chiryo 1997 Jan; 25: 227-44
24. Yui Y, Kawai C, Hosoda S, et al. A double-blind, dose-finding study for the i.v. bolus injection of SUN9216 (modified tissue plasminogen activator) in acute myocardial infarction: clinical late phase II study [in Japanese]. Yakuri to Chiryo 1997 Jan; 25: 245-67
25. Yui Y, Kawai C, Hosoda S. Clinical efficacy of SUN9216 (modified tissue plasminogen activator) as compared to alteplase in patients with acute myocardial infarction: a multicenter randomized double-blind comparative study [in Japanese]. Yakuri to Chiryo 1997 Jan; 25: 269-99
26. Earl T, Walsh C. New thrombolytics look as good as alteplase.Inpharma 1999 May 1; 1185: 9-10
27. New single-bolus thrombolytics ease administration, match t-PA in efficacy. Formulary 1999; 34 (5): 461-2